Deferred Tax Assets, Valuation Allowance of Aldeyra Therapeutics, Inc. from 31 Dec 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Aldeyra Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2013 to 31 Dec 2025.
  • Aldeyra Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $130,890,968, a 7.7% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Aldeyra Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $130,890,968 +$9,404,493 +7.7% 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q4 2024 $121,486,475 +$16,643,618 +16% 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q4 2023 $104,842,857 +$10,214,058 +11% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q4 2022 $94,628,799 +$17,801,596 +23% 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q4 2021 $76,827,203 +$18,115,621 +31% 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q4 2020 $58,711,582 +$8,546,155 +17% 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q4 2019 $50,165,427 +$15,793,831 +46% 31 Dec 2019 10-K 11 Mar 2021 2020 FY
Q4 2018 $34,371,596 +$12,248,304 +55% 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q4 2017 $22,123,292 +$336,815 +1.5% 31 Dec 2017 10-K 08 Mar 2019 2018 FY
Q4 2016 $21,786,477 +$7,368,382 +51% 31 Dec 2016 10-K 29 Mar 2018 2017 FY
Q4 2015 $14,418,095 +$4,843,343 +51% 31 Dec 2015 10-K 30 Mar 2017 2016 FY
Q4 2014 $9,574,752 +$16,360,884 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q4 2013 $6,786,132 31 Dec 2013 10-K 23 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.